Pilot study of fluzinamide (N-methyl-3-[3-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide) in refractory partial seizures.
We conducted a pilot study of fluzinamide in 15 adults with refractory partial seizures. After a baseline period, fluzinamide was added to the existing regimen of phenytoin and carbamazepine and increased to maximum tolerated dose. Common side effects included dizziness, diplopia, ataxia, headache, nausea, and rash, resulting in patient withdrawal in six cases. Seizures became less frequent in four of the nine patients who completed the 8-week trial.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D001384:Azetidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001385:Azetines / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000139:chemically induced; D004351:Drug Resistance; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012640:Seizures / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D012871:Skin Diseases / Q000139:chemically induced
D000927:Anticonvulsants; D001384:Azetidines; D001385:Azetines; C042116:fluzinamide